A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : BPH / benign hyperplasia

[Related PubMed/MEDLINE]
Total Number of Papers: 52
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   BPH  (>> Co-occurring Abbreviation)
Long Form:   benign hyperplasia
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2022 Clinicopathological Significance of Exosomal Proteins CD9 and CD63 and DNA Mismatch Repair Proteins in Prostate Adenocarcinoma and Benign Hyperplasia. IHC, MMR, PCa, PFS
2021 Lectins applied to diagnosis and treatment of prostate cancer and benign hyperplasia: A review. PCa
2020 The Urinary Transcriptome as a Source of Biomarkers for Prostate Cancer. dd, NGS, PCa
2019 Novel Gastrin-Releasing Peptide Receptor Targeted Near-Infrared Fluorescence Dye for Image-Guided Surgery of Prostate Cancer. BBN, GRPR, NIRF, PCa
2017 Effects of a co-micronized composite containing palmitoylethanolamide and polydatin in an experimental model of benign prostatic hyperplasia. PEA, PLD
2017 Searching for prostate cancer by fully automated magnetic resonance imaging classification: deep learning versus non-deep learning. AUC, BCs, BoW, DCNN, PCa
2016 Activation of AKT negatively regulates the pro-apoptotic function of death-associated protein kinase 3 (DAPK3) in prostate cancer. DAPK3
2014 Chronic inflammation of the prostate type IV with respect to risk of prostate cancer. CII, HGPCA, PCa
10  2014 Galphas protein expression is an independent predictor of recurrence in prostate cancer. PSA
11  2011 On chip immuno-affinity profiling of cancer- and benign hyperplasia-associated free prostate specific antigen. fPSA, PSA
12  2010 Conventional monopolar resection or bipolar resection in saline for the management of large (>60 g) benign prostatic hyperplasia: an evaluation of morbidity. TURIS
13  2008 Combined analysis of multiple mRNA markers by RT-PCR assay for prostate cancer diagnosis. PCa
14  2007 A variant epidermal growth factor receptor protein is similarly expressed in benign hyperplastic and carcinomatous prostatic tissues in black and white men. ---
15  2007 Aneuploidy of chromosome Y in prostate tumors and seminal vesicles: a possible sign of aging rather than an indicator of carcinogenesis? BC, FISH, PCa
16  2007 [Evaluation of radiofrequency (TUNA) in the outpatient treatment of benign prostatic hyperplasia]. IPSS, QOL-UR, TUNA
17  2006 Comparison between two commercially available chromogranin A assays in detecting neuroendocrine differentiation in prostate cancer and benign prostate hyperplasia. CgA, ELISA, IRMA, NE, PC, pts
18  2003 [An artificial neural network as a tool in risk evaluation of prostate cancer. Indication for biopsy with the PSA range of 2-20 microg/l]. ANN
19  2001 Differential expression of interleukin-15, a pro-inflammatory cytokine and T-cell growth factor, and its receptor in human prostate. IL, IL-15R, PSC
20  2000 Botanical derivatives for the prostate. ---
21  2000 Comparison of the activation status of tumor infiltrating and peripheral lymphocytes of patients with adenocarcinomas and benign hyperplasia of the prostate. PCa, TIL
22  1999 Phytoestrogens and diseases of the prostate gland. EGF, FGFs, KGF
23  1998 Expression of macrophage migration inhibitory factor in the human prostate. ELISA, IHC, MIF
24  1998 Expression of the aryl hydrocarbon receptor (AhR) and the aryl hydrocarbon receptor nuclear translocator (ARNT) in fetal, benign hyperplastic, and malignant prostate. AhR, ARNT, EC
25  1998 Prostate, breast and gynecological cancer markers RAK with homology to HIV-1. PCR
26  1997 Intra- and interobserver variability of MRI prostate volume measurements. MRI
27  1996 Evaluation of transurethral vaporization of prostate with pressure-flow analysis and other clinical measures. PVR, TUVP
28  1996 Hypermethylation of chromosome 17P locus D17S5 in human prostate tissue. ---
29  1996 Identification of endothelin receptors in normal and hyperplasic human prostate tissues. ET-1
30  1996 [Treatment of prostate benign hyperplasia (BPH) with visually controlled laser, assessment at 2 years, and anatomopathologic findings]. ---
31  1995 Quantitative and qualitative AgNORs rates of prostate cancer on needle core biopsies: a multicentric study. GLG, PrC, PSA, SFCP
32  1994 Ejaculatory dysfunction after transurethral microwave thermotherapy for treatment of benign prostatic hyperplasia. TUMT
33  1994 Relationship between serum prostate specific antigen and histological prostatitis in patients with benign prostatic hyperplasia. PSA
34  1994 [Tumor markers in prostate cancer]. PSA
35  1993 Citrate alterations in primary and metastatic human prostatic adenocarcinomas: 1H magnetic resonance spectroscopy and biochemical study. ---
36  1993 Detection of human papillomavirus 16 transcription in human prostate tissue. PCR
37  1993 Effects of suramin on the proliferation of primary epithelial cell cultures derived from normal, benign hyperplastic and cancerous human prostates. BPE, PECs
38  1992 Hormonal modulation of biosynthesis of prostatic specific antigen, prostate specific acid phosphatase and prostatic inhibin peptide. PIP, PSA, PSAP
39  1992 Immunohistochemistry and biochemistry in detection of androgen, progesterone, and estrogen receptors in benign and malignant human prostatic tissue. AR, ER, PR
40  1992 P53 and Ki-67 immunoreactivity in human prostate cancer and benign hyperplasia. ---
41  1991 Steroid receptor profile and receptor stability in subfractions of human prostatic tissues. Critical aspects on microassays. AR, ER, PR
42  1990 Pathology of benign prostatic hyperplasia. Insight into etiology. ---
43  1989 Immunohistochemical localization of laminin in the basement membranes of normal, hyperplastic, and neoplastic human prostate. BM, IF, IP
44  1988 Effect of stilboestrol and testosterone on the incorporation of 75selenomethionine by prostatic carcinoma cells. SeM
45  1987 Comparative study of plasma steroid and steroid glucuronide levels in normal men and in men with benign prostatic hyperplasia. ---
46  1986 Concentrations of 3 beta-hydroxy androgens in epithelium and stroma of benign hyperplastic and normal human prostate. 3 beta-hydroxy-5-androsten-17-one, DHEA, A-Diol
47  1986 Growth responses of normal, benign hyperplastic, and malignant human prostatic epithelial cells in vitro to cholera toxin, pituitary extract, and hydrocortisone. EGF
48  1985 Creatine phosphokinase isoenzymes in human prostatic tissues: a comparison between benign hyperplasia and adenocarcinoma. CPK, PAP
49  1982 Melanin-like pigment in the human prostate. ---
50  1982 Plasminogen activator activity in human prostate and breast tumors: relationship to steroid receptors. ER, PA, PR
51  1982 Testosterone metabolism of fibroblasts grown from prostatic carcinoma, benign prostatic hyperplasia and skin fibroblasts. NG, PC
52  1977 Correlative study of the morphology and C19-steroid metabolism of benign and cancerous human prostatic tissue. ---